Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real World Study Investigating the Long Term Efficacy and Safety of Nimotuzumab with Concurrent Chemoradiotherapy (CCRT) in Patients with Unresectable Locally Advanced Head and Neck Cancer

Trial Profile

A Real World Study Investigating the Long Term Efficacy and Safety of Nimotuzumab with Concurrent Chemoradiotherapy (CCRT) in Patients with Unresectable Locally Advanced Head and Neck Cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jun 2018 New trial record
    • 05 Jun 2018 According to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology, patients were included in this study between October 2010 to November 2016.
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top